Vivos Therapeutics Files Form 8-K/A with the SEC
Summary
Vivos Therapeutics has submitted an amended Form 8-K/A filing to the U.S. Securities and Exchange Commission.
Prepared by the newsroom with AI assistance; the original link is always provided
Vivos Therapeutics, Inc. has filed an amended Form 8-K/A with the U.S. Securities and Exchange Commission (SEC).
The regulatory filing discloses the company's entry into a material definitive agreement and reports unregistered sales of equity securities. The document also includes relevant financial statements and exhibits.
Source: SEC EDGAR
Read the original →Latest news
Bank CenterCredit Repurchases Shares for 18.2B Tenge on KASE
Bank CenterCredit JSC has repurchased 4.1 million of its common shares on the Kazakhstan Stock Exchange for 18.2 billion tenge.
Source: KASE
Home Credit Bank Bonds Added to KASE T+ List
Starting October 8, Home Credit Bank bonds (KZQ000001213, HCBNe1) will be included in the KASE T+ List.
Source: KASE
KASE Publishes Member Activity Rankings for September 2026
Kazakhstan Stock Exchange has released its exchange member activity rankings for September 2026 on its official website.
Source: KASE
KASE Index rises 0.25% to 7,862.81 points
On October 7, the KASE Index climbed by 0.25% to settle at 7,862.81 points.
Source: KASE